ClinicalTrials.Veeva

Menu

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab (NAVIGATE)

C

Christoph Königs

Status

Enrolling

Conditions

Severe Hemophilia A
Severe Hemophilia A Without Inhibitor
Severe Hemophilia A With Inhibitor

Treatments

Other: no interventions

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05802836
DRKS00031196 (Registry Identifier)
ML44394

Details and patient eligibility

About

The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.

Enrollment

100 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Severe congenital hemophilia A (CHA)
  • Treatment with emicizumab irrespective of any other treatment
  • Informed consent

Exclusion criteria

  • No therapy with emicizumab
  • Immunosuppressive therapy
  • HIV-infection with CD4 (cluster of differentiation 4) cells <200/µl

Trial design

100 participants in 3 patient groups

Inhibitor negative, FVIII on demand or regularly
Description:
Patients with severe hemophilia A receiving emicizumab therapy which are negative for factor VIII Inhibitor (including patients post ITI) and are receiving factor VIII therapy either on demand or regularly,
Treatment:
Other: no interventions
Inhibitor positive, FVIII therapy regularly (ITI)
Description:
Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving regularly factor VIII therapy (ITI)
Treatment:
Other: no interventions
Inhibitor positive, no FVIII therapy
Description:
Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving no factor VIII therapy
Treatment:
Other: no interventions

Trial contacts and locations

1

Loading...

Central trial contact

Christoph Koenigs, PD Dr. Dr; Stephan Schultze-Strasser, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems